Calidi Biotherapeutics, Inc. (CLDI) - Form 8-K Summary
Business Context and Reporting Period
Calidi Biotherapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on November 12, 2024. The filing serves to disclose the Company's financial results for the third quarter ended September 30, 2024, and recent corporate developments via a press release incorporated as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced in a separate press release (Exhibit 99.1) rather than detailing the figures within the 8-K body.
Material Changes
The filing references "certain financial results" and "certain recent corporate developments" for the third quarter of 2024. However, the text does not specify the nature or magnitude of changes compared to the prior comparable period.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, or unusual items are not detailed in this filing text. The report explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, directing readers to the press release for full details.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 12, 2024) for specific Q3 2024 financial figures.
- Verify the details of the "recent corporate developments" mentioned in the press release.
- Confirm the Company's cash runway and liquidity position as disclosed in the full press release.
- Check for any updates to clinical trial timelines or regulatory milestones referenced in the corporate developments.